Bilgic, Ozlem2020-03-262020-03-2620161556-95271556-9535https://dx.doi.org/10.3109/15569527.2015.1100635https://hdl.handle.net/20.500.12395/34196Vemurafenib, a novel treatment for patients with BRAF-positive metastatic melanoma, is associated with a wide spectrum of cutaneous adverse events both benign and malignant. Vemurafenib-induced pityriasis amiantacea (PA), a scaling reaction of the scalp that may cause temporary or cicatricial alopecia, has not yet been reported in the literature. In the present case, PA was observed two months after the initiation of vemurafenib therapy for metastatic melanoma and managed with symptomatic treatment without the need to cease or modify the vemurafenib dosage.en10.3109/15569527.2015.1100635info:eu-repo/semantics/closedAccessBRAF inhibitorcutaneous side effectsdermatitiseruptive miliamelanomaphotosensitivityseborrheic dermatitis like eruptiontinea amiantaceaArticle35432933126513697Q3WOS:000384429000011Q4